AIM-Harvard/TrialPanorama-filtered huggingface dataset:
Study NCT02212574 — intervention group
Intervention type: DRUG
Group type: OTHER
Intervention: Vincristine
Description: Chemotherapy Cycle B Vincristine is given directly into a vein directly into the vein (IV) over one minute or using a minibag over several minutes by some institutions on Days 1 and 8.
Study NCT00443976 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Aurora kinase inhibitor AT9283
Description: The starting dose of AT9283 will be 1.5 mg/m2 given as a 24 hour IV infusion on Days 1 and 8 every three weeks.
Study NCT04794803 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Reparixin
Description: Reparixin was administered via oral tablets 1200 mg TID for 7 days. In case of improvement, treatment can be prolonged at discretion of the investigator up to a maximum of 21 days of treatment in total or live discharge from the hospital, whichever comes first.
Study NCT04794803 — intervention group
Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Standard of care
Description: Standard of care
Study NCT02077257 — intervention group
Intervention type: DRUG
Group type: OTHER
Intervention: Rosuvastatin
Description: Rosuvastatin 20 mg/d compared to 10 mg/day
Study NCT02901457 — intervention group
Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: The Healthy Body Image intervention
Description: Interactive workshops (3 x 90 minutes) include training techniques to increase media literacy, enhance self-esteem, positive body image, awareness of perfectionism, and include discussions related to truths and myths related to life style factors. Homework is an extension of each workshop that is simple and not time-consuming tasks to increase reflection and awareness of how all the mentioned factors are a part of their lives.
Study NCT01494831 — intervention group
Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: TF-CBT
Description: 15 sessions of group-based, trauma-focused cognitive behavioral therapy
Study NCT01046305 — intervention group
Intervention type: BEHAVIORAL
Intervention: Interview & Questionnaires
Description: 30 Minute Interview about what it is like to have CML, followed by symptom questionnaire, quality-of-life questionnaire, and demographic questions taking another 10 minutes for all 3 questionnaires.
Study NCT01046305 — intervention group
Intervention type: BEHAVIORAL
Intervention: Rating Questionnaire
Description: Questionnaire developed in Part 1 to rate the relevance of symptom items, given to 3-5 physicians, 3-5 nurses, 2-4 patients and their family caregivers, taking about 10 minutes.
Study NCT01046305 — intervention group
Intervention type: BEHAVIORAL
Intervention: MDASI-CML Questionnaire
Description: Patient questionnaires about CML symptoms over 1 year, completed in person or using Interactive Voice Response (IVR) system every 2 weeks.
Study NCT04109703 — intervention group
Intervention type: DEVICE
Group type: ACTIVE_COMPARATOR
Intervention: High Level Pulsed Heat delivered by Generation 5 devices from Soovu Labs Inc.
Description: The Soovu Labss Inc. battery powered device is a one inch diameter heating pod that attaches to the user via a ring system. The device may be programmed to deliver a wide variety of treatment algorithms. Control of the devices are through a phone-based bluetooth connection. For this study the treatment algorithm used for subjects in this arm (experimental) used a temperature that was ramped from skin temperature to a peak temperature of 45° C and cycled for 30 minutes.
Study NCT04109703 — intervention group
Intervention type: DEVICE
Group type: PLACEBO_COMPARATOR
Intervention: Low Level (37 degrees C) delivered by the control device Generation 5 devices from Soovu Labs Inc.
Description: The Soovu Labs Inc. battery powered device is a one inch diameter heating pod that attaches to the user via a ring system. The device may be programmed to deliver a wide variety of treatment algorithms. Control of the devices are via a phone-based bluetooth connection. For this control arm of the study the treatment algorithm held a steady temperature of 37 degrees C for a 30 minute period.
Study NCT04699266 — intervention group
Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: Assigned Intervention (POD F GF)
Description: The investigational lens (POD F GF )will be implanted to both eyes in subjects with bilateral cataract. Registration of patients and the implantation of the investigational lens (POD F GF) will be conducted in consideration of securing 44 eyes in 22 subjects as the analysis subjects
Study NCT02750254 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Fludarabine
Study NCT02750254 — intervention group
Intervention type: RADIATION
Group type: EXPERIMENTAL
Intervention: Fractionated total body irradiation
Study NCT02750254 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Busulfan
Study NCT02750254 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Cyclophosphamide
Study NCT02750254 — intervention group
Intervention type: RADIATION
Group type: EXPERIMENTAL
Intervention: Single dose total body irradiation
Study NCT02750254 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Melphalan
Study NCT02750254 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Granulocyte-colony stimulating factor
Study NCT02750254 — intervention group
Intervention type: PROCEDURE
Group type: EXPERIMENTAL
Intervention: Stem cell transplant
Study NCT02750254 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Azacitidine
Study NCT00423176 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: MFNS and antibiotic
Description: MFNS BID for 29 days plus amoxicillin/clavulanic acid BID for 10 days
Study NCT00423176 — intervention group
Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Matching Placebo nasal spray plus antibiotic
Description: Matching placebo nasal spray BID for 29 days plus amoxicillin/clavulanic acid BID for 10 days
Study NCT04447326 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Toripalimab, Endostar Combined With Radiotherapy and Chemotherapy
Description: Toripalimab: 240 mg, Q3W, starting on D1, for totally 12 cycles Endostar: 7.5 mg/m2/d, continuous intravenous pumping for 10 days, Q3W, starting on D1, for totally 5 cycles
Study NCT04447326 — intervention group
Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: IC＋CCRT
Description: IC＋CCRT
Study NCT02710799 — intervention group
Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Teleconsultation
Description: The teleconsultations will be performed by medical doctors, mostly family physicians, but also internists and endocrinologists. The teleconsultations will follow a structured format to discuss some topics on the disease and access the relevant information (based on the state's protocols). The doubts from the primary care physician will be addressed.
Study NCT02710799 — intervention group
Intervention type: OTHER
Group type: ACTIVE_COMPARATOR
Intervention: Protocol
Description: The informations provided in the referral list will be evaluated through the state's referrals protocols.
Study NCT02710799 — intervention group
Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Protocol
Description: The informations provided in the referral list will be evaluated through the state's referrals protocols.
Study NCT01227668 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Aripiprazole
Description: Tablets, Oral, 2-15 mg, once daily, 13-42 weeks
Study NCT01227668 — intervention group
Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Placebo
Description: Tablets, Oral, 0 mg, once daily, 16 weeks
Study NCT04321239 — intervention group
Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Positive STEPS
Description: Individuals in the intervention group will meet with a community health worker at an in-person or virtual study orientation session. At this session, they will be introduced to the program, learn how to use the online modules and any associated materials, and choose a day and time for future weekly telephone sessions. Participants will also be given a wearable physical activity tracker at the orientation session to use throughout the course of the program. They can choose to report daily step counts either by automatically syncing to an app or by manual reporting via text message. The program will be delivered over 6 weeks. Each week participants will complete a web-based module and have one telephone session with the community health worker to discuss that module and to set a related goal. Participants will also set weekly goals related to walking, which will be informed and tracked by daily step-counts from the physical activity tracker.
Study NCT02444390 — intervention group
Intervention type: PROCEDURE
Group type: OTHER
Intervention: Biopsy
Description: biopsy of a metastasis
Study NCT01965561 — intervention group
Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: CRoC
Description: Use of Combat Ready Clamp (CRoC)
Study NCT01965561 — intervention group
Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: AAJT
Description: Use of Abdominal Aortic and Junctional Tourniquet (AAJT)
Study NCT01965561 — intervention group
Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: JETT
Description: Use of Junctional Emergency Treatment Tool (JETT)
Study NCT01965561 — intervention group
Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: SJT
Description: Use of SAM Junctional Tourniquet (SJT)
Study NCT01164423 — intervention group
Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: Space TGC
Description: Space TGC with incorporated eMPC algorithm to establish glycaemic control with a blood glucose target range of 80-150 mg/dL (4.4-8.3 mM)
Study NCT04189094 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Sintilimab
Description: Etoposide and cisplatin (carboplatin) plus Sintilimab induction therapy will be administered for 2 cycles and then thoracic radiotherapy (45 Gy/30 fractions) be administered with concurrent EP/EC chemotherapy for 2cycles. Patients who achieve CR or PR then receive prophylactic cranial irradiation (PCI, 25 Gy/10 fractions).Sintilimab maintenance therapy will be administered once every 3 week for 13 cycles.
Study NCT04189094 — intervention group
Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Etoposide
Description: Etoposide will be administered IV 100mg/m2 on days 1-3, 22-24, 43-45 and 64-66.
Study NCT04189094 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Etoposide
Description: Etoposide will be administered IV 100mg/m2 on days 1-3, 22-24, 43-45 and 64-66.
Study NCT04189094 — intervention group
Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Cisplatin
Description: cisplatin will be administered IV 80mg/m2 on days 1, 22, 43 and 64.
Study NCT02346838 — intervention group
Intervention type: DIETARY_SUPPLEMENT
Group type: EXPERIMENTAL
Intervention: Inulin
Description: The treatment will be mixed in orange juice or other beverage and will be consumed at breakfast each day in our metabolic kitchen.
Study NCT02346838 — intervention group
Intervention type: DIETARY_SUPPLEMENT
Group type: PLACEBO_COMPARATOR
Intervention: Placebo
Description: The placebo will be mixed in orange juice or other beverage and will be consumed at breakfast each day in our metabolic kitchen.
Study NCT00601939 — intervention group
Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Psychoeducational intervention (PEI)
Description: PEI consists of 10 culturally competent group empowerment psychoeducational sessions. The sessions are directed by a treatment manual and are co-led by two therapists. The sessions are guided by the theory of triadic influence (TTI) model, which incorporates cultural-environmental influences, social-situational influences, and intrapersonal influences into treatment.
Study NCT00537758 — intervention group
Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Cognitive Behavior Therapy
Study NCT00601939 — intervention group
Intervention type: BEHAVIORAL
Group type: ACTIVE_COMPARATOR
Intervention: Enhanced treatment as usual (ETAU)
Description: ETAU contains an adherence protocol plus access to weekly support group and a resource room.
Study NCT00537758 — intervention group
Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: CBT and BWL
Study NCT00537758 — intervention group
Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Behavioral Weight Loss Treatment
Study NCT04189094 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Cisplatin
Description: cisplatin will be administered IV 80mg/m2 on days 1, 22, 43 and 64.
Study NCT04189094 — intervention group
Intervention type: RADIATION
Group type: ACTIVE_COMPARATOR
Intervention: radiotherapy
Description: Thoracic radiotherapy (45 Gy/30 fractions) and prophylactic cranial irradiation (25 Gy/10 fractions).
Study NCT04189094 — intervention group
Intervention type: RADIATION
Group type: EXPERIMENTAL
Intervention: radiotherapy
Description: Thoracic radiotherapy (45 Gy/30 fractions) and prophylactic cranial irradiation (25 Gy/10 fractions).
Study NCT02632656 — intervention group
Intervention type: OTHER
Intervention: Monitoring on heart failure therapy
Description: This is a prospective observational study where participants will have serial blood collection on medical therapy for heart failure.
Study NCT03877055 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Copanlisib
Description: Treatment will be with intravenous copanlisib on days 1, 8, 15 of 28 day cycles.
Study NCT03877055 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Ibrutinib
Description: Oral ibrutinib daily in 28 day cycles. A cycle is defined as 28 days of therapy.
Study NCT03611114 — intervention group
Intervention type: DIETARY_SUPPLEMENT
Group type: EXPERIMENTAL
Intervention: Blood orange juice
Study NCT03611114 — intervention group
Intervention type: DIETARY_SUPPLEMENT
Group type: PLACEBO_COMPARATOR
Intervention: Control drink
Study NCT03449628 — intervention group
Intervention type: DIETARY_SUPPLEMENT
Group type: EXPERIMENTAL
Intervention: L.casei DG
Description: (At least 24 billion live cells per capsule)~1 capsule, b.i.d. for 12 weeks
Study NCT03449628 — intervention group
Intervention type: DIETARY_SUPPLEMENT
Group type: PLACEBO_COMPARATOR
Intervention: PLACEBO
Description: 1 capsule, b.i.d. for 12 weeks
Study NCT01211769 — intervention group
Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Naltrexone
Description: A pill of naltrexone chlorhydrate 50mg, associated to yellow liquid paraffin pills simulating borage seed and fish oil.
Study NCT01211769 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: PUFAs
Description: Borage Oil (Borago officinalis L. Boraginaceae) - rich in omega 6 PUFA, dosage of 1 gram and Fish oil 1 gram - rich in omega 3 PUFAs; associated to a pill with 50mg of talcum powder, identical to the pill of naltrexone.
Study NCT04546009 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Giredestrant
Description: Giredestrant is taken orally once per day on Days 1-28 of each 28-day treatment cycle.
Study NCT04546009 — intervention group
Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Giredestrant-matched Placebo
Description: Giredestrant-matched placebo is taken orally once per day on Days 1-28 of each 28-day treatment cycle.
Study NCT04546009 — intervention group
Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Letrozole
Description: Letrozole 2.5 milligrams (mg) is taken orally once per day on Days 1-28 of each 28-day treatment cycle.
Study NCT04546009 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Letrozole-matched Placebo
Description: Letrozole-matched placebo is taken orally once per day on Days 1-28 of each 28-day treatment cycle.
Study NCT04546009 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Palbociclib
Description: Palbociclib 125 mg is taken orally once per day on Days 1-21 of each 28-day treatment cycle.
Study NCT04546009 — intervention group
Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Palbociclib
Description: Palbociclib 125 mg is taken orally once per day on Days 1-21 of each 28-day treatment cycle.
Study NCT04546009 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: LHRH Agonist
Description: Only premenopausal/perimenopausal and male participants will receive a luteinizing hormone-releasing hormone (LHRH) agonist on Day 1 of each 28-day treatment cycle. The investigator will determine and supply the appropriate LHRH agonist locally approved for use in breast cancer.
Study NCT04546009 — intervention group
Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: LHRH Agonist
Description: Only premenopausal/perimenopausal and male participants will receive a luteinizing hormone-releasing hormone (LHRH) agonist on Day 1 of each 28-day treatment cycle. The investigator will determine and supply the appropriate LHRH agonist locally approved for use in breast cancer.
Study NCT05142059 — intervention group
Intervention type: DIAGNOSTIC_TEST
Group type: EXPERIMENTAL
Intervention: Exploratory physiopathology study, including non-invasive functional explorations carried out in patients with Charcot-Marie-Tooth disease type 1A
Description: The data of the gait analysis, posturography and strength analyses as well as the questionnaires' scores will be taken into account in this research. At 6 months and at 1 year, occurrence of a fall will be recorded in order to prospectively monitor this parameter. A final analysis will be carried out at 1 year from the first according to the same methods as the initial assessment.
Study NCT02863718 — intervention group
Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Ibrutinib
Description: Bruton's tyrosine kinase Inhibitor Ibrutinib 420mg daily
Study NCT02863718 — intervention group
Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Placebo
Description: Placebo 420mg daily
Study NCT03368092 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Dornase Alfa Inhalant Solution [Pulmozyme]
Description: Dornase alfa (Pulmozyme®, Roche 2500U, 2,5mL) given by aerosol in the respiratory circuit (Aerogen solo®) within 6h at day 1 and 24 hours after on day 2.
Study NCT03368092 — intervention group
Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Placebos
Description: NaCl 0,9%, given by aerosol in the respiratory circuit within 6h at day 1 and 24 hours after on day 2.
Study NCT00470717 — intervention group
Intervention type: PROCEDURE
Group type: OTHER
Intervention: Weekly telephone call
Description: Details of feeding and health/sickness will be obtained
Study NCT00512070 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: olanzapine and melatonin
Description: In treatment phase I, all subjects will receive olanzapine, 10-25 mg/day. In treatment phase II, all subjects will receive olanzapine (10-25 mg/day) plus melatonin. Subjects will be randomized at a ratio of 1:1 to receive melatonin, 0.3 mg/day or 3.0 mg/day. Group IIA will receive 0.3mg day melatonin. Group IIB will receive 3.0 mg/day melatonin.
Study NCT04382404 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Sofosbuvir-Velpatasvir Drug Combination
Description: One oral pill containing 400mg sofosbuvir and 100mg velpatasvir taken once daily for 12 weeks
Study NCT03964675 — intervention group
Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: SenseGuard
Description: A single invitational visit with a respiratory rate measurement duration of 30 minutes.
Study NCT01134107 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Insulin Lispro 6 Day (6D)
Description: Administered by infusion pump for 12 week treatment period
Study NCT01134107 — intervention group
Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Insulin Aspart 6 Day (6D)
Description: Administered by infusion pump for 12 week treatment period
Study NCT00557544 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: metoclopramide
Description: metoclopramide 0,15 mg/kg
Study NCT00557544 — intervention group
Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: metoclopramide
Description: metoclopramide 0,15 mg/kg
Study NCT00557544 — intervention group
Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: placebo
Description: placebo per os
Study NCT00557544 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: ketoprofen
Description: ketoprofen 1 mg/Kg
Study NCT00557544 — intervention group
Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: ketoprofen
Description: ketoprofen 1 mg/Kg
Study NCT00006178 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Sirolimus
Study NCT00006178 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Thymoglobulin
Study NCT00418886 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Vandetanib
Description: oral once daily tablet
Study NCT00418886 — intervention group
Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Pemetrexed
Description: intravenous infusion
Study NCT00418886 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Pemetrexed
Description: intravenous infusion
Study NCT01134614 — intervention group
Intervention type: BIOLOGICAL
Group type: EXPERIMENTAL
Intervention: Ipilimumab
Description: Given IV
Study NCT00853645 — intervention group
Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: Subcutaneous Implantable Defibrillator (S-ICD) System
Study NCT01134614 — intervention group
Intervention type: BIOLOGICAL
Group type: ACTIVE_COMPARATOR
Intervention: Ipilimumab
Description: Given IV
Study NCT01134614 — intervention group
Intervention type: BIOLOGICAL
Group type: EXPERIMENTAL
Intervention: Sargramostim
Description: Given SC
Study NCT02602990 — intervention group
Intervention type: DEVICE
Intervention: SQUID™
Study NCT04054115 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Alprostadil 5 MCG Injection
Description: During the MRI, Alprostadil infusion will be started and titrated to the target dose, ensuring there is a less than 20% drop in blood pressure from baseline. Repeat pressure and MRI flow measurements once Alprostadil reaches 0.1mcg/kg/min.
Study NCT03469856 — intervention group
Intervention type: DRUG
Group type: OTHER
Intervention: Prasugrel monotherapy
Description: A multicenter, single arm, open-label trial of in patients with chronic stable angina
Study NCT00726973 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Ranibizumab
Description: Ranibizumab, and reduced fluence PDT or sham PDT and Ranibizumab. For 2 months injected intravitreal Ranibizumab will be given. At month 3 subjects will receive combination reduced fluence PDT and intravitreal Ranibizumab. If they develop recurrence of subretinal fluid, cystoid macular edema, increased pigment epithelial detachment (PED), or increased retinal thickness >100 microns compared to best thickness measure of OCT, subjects will be eligible for repeat combination reduced fluence PDT + intravitreal Ranibizumab every 3 months thereafter.